Wall Street equity research analysts and institutional forecasting models view Agenus (AGEN) through a high-risk, high-reward lens typical of clinical-stage biotechnology firms. Consensus price targets span a broad range, reflecting the binary nature of upcoming clinical data readouts and regulatory milestones. While bullish forecasts highlight exponential upside potential if their combination therapies and antibody pipelines secure pharmaceutical partnerships or approvals, conservative models account for continuous cash burn and regulatory headwinds.